O	0	8	Vimentin	Vimentin	NN	B-NP
O	9	11	is	be	VBZ	B-VP
O	12	26	preferentially	preferentially	RB	I-VP
O	27	36	expressed	express	VBN	I-VP
O	37	39	in	in	IN	B-PP
O	40	45	human	human	JJ	B-NP
B-Cancer	46	52	breast	breast	NN	I-NP
I-Cancer	53	63	carcinomas	carcinoma	NNS	I-NP
O	64	68	with	with	IN	B-PP
O	69	72	low	low	JJ	B-NP
O	73	81	estrogen	estrogen	NN	I-NP
O	82	90	receptor	receptor	NN	I-NP
O	91	94	and	and	CC	O
O	95	99	high	high	JJ	B-NP
O	100	102	Ki	Ki	NN	I-NP
O	102	103	-	-	HYPH	B-NP
O	103	105	67	67	CD	I-NP
O	106	112	growth	growth	NN	I-NP
O	113	121	fraction	fraction	NN	I-NP
O	121	122	.	.	.	O

O	124	132	Vimentin	Vimentin	NN	B-NP
O	133	143	expression	expression	NN	I-NP
O	143	144	,	,	,	O
O	145	151	growth	growth	NN	B-NP
O	152	161	fractions	fraction	NNS	I-NP
O	162	163	(	(	(	O
O	163	165	GF	GF	NN	B-NP
O	165	166	)	)	)	O
O	166	167	,	,	,	O
O	168	171	and	and	CC	O
O	172	180	estrogen	estrogen	NN	B-NP
O	181	189	receptor	receptor	NN	I-NP
O	190	191	(	(	(	O
O	191	193	ER	ER	NN	B-NP
O	193	194	)	)	)	O
O	195	201	levels	level	NNS	B-NP
O	202	206	were	be	VBD	B-VP
O	207	217	determined	determine	VBN	I-VP
O	218	221	for	for	IN	B-PP
O	222	224	90	90	CD	B-NP
O	225	234	untreated	untreated	JJ	I-NP
B-Cancer	235	242	primary	primary	JJ	I-NP
I-Cancer	243	249	breast	breast	NN	I-NP
I-Cancer	250	260	carcinomas	carcinoma	NNS	I-NP
O	260	261	.	.	.	O

O	262	274	Coexpression	Coexpression	NN	B-NP
O	275	277	of	of	IN	B-PP
O	278	285	keratin	keratin	NN	B-NP
O	286	289	and	and	CC	I-NP
O	290	298	vimentin	vimentin	NN	I-NP
O	299	302	was	be	VBD	B-VP
O	303	308	found	find	VBN	I-VP
O	309	311	in	in	IN	B-PP
O	312	325	approximately	approximately	RB	B-NP
O	326	328	20	20	CD	I-NP
O	328	329	%	%	NN	I-NP
O	330	332	of	of	IN	B-PP
O	333	336	the	the	DT	B-NP
B-Cancer	337	343	tumors	tumor	NNS	I-NP
O	344	354	regardless	regardless	RB	B-ADVP
O	355	357	of	of	IN	B-PP
O	358	368	menopausal	menopausal	JJ	B-NP
O	369	375	status	status	NN	I-NP
O	375	376	.	.	.	O

O	377	385	Vimentin	Vimentin	NN	B-NP
O	386	389	was	be	VBD	B-VP
O	390	399	expressed	express	VBN	I-VP
O	400	414	preferentially	preferentially	RB	B-ADVP
O	415	417	in	in	IN	B-PP
B-Cell	418	423	tumor	tumor	NN	B-NP
I-Cell	424	429	cells	cell	NNS	I-NP
O	430	432	of	of	IN	B-PP
B-Cancer	433	437	high	high	JJ	B-NP
I-Cancer	437	438	-	-	HYPH	I-NP
I-Cancer	438	443	grade	grade	NN	I-NP
I-Cancer	444	450	ductal	ductal	JJ	I-NP
I-Cancer	451	457	breast	breast	NN	I-NP
I-Cancer	458	468	carcinomas	carcinoma	NNS	I-NP
O	469	470	(	(	(	O
O	470	472	15	15	CD	B-NP
O	473	475	of	of	IN	B-PP
O	476	478	28	28	CD	B-NP
O	479	489	histologic	histologic	JJ	I-NP
O	490	495	grade	grade	NN	I-NP
O	496	497	3	3	CD	B-NP
O	498	500	vs	v	NNS	I-NP
O	500	501	.	.	.	O
O	502	503	0	0	CD	B-NP
O	504	506	of	of	IN	B-PP
O	507	509	40	40	CD	B-NP
O	510	516	grades	grade	NNS	I-NP
O	517	518	1	1	CD	I-NP
O	519	522	and	and	CC	I-NP
O	523	524	2	2	CD	I-NP
O	524	525	)	)	)	O
O	525	526	.	.	.	O

O	527	535	Vimentin	Vimentin	NN	B-NP
O	536	546	expression	expression	NN	I-NP
O	547	550	was	be	VBD	B-VP
O	551	556	found	find	VBN	I-VP
O	557	571	preferentially	preferentially	RB	B-ADVP
O	572	574	in	in	IN	B-PP
B-Cancer	575	581	tumors	tumor	NNS	B-NP
O	582	586	with	with	IN	B-PP
O	587	591	high	high	JJ	B-NP
O	592	594	GF	GF	NN	I-NP
O	595	596	(	(	(	O
O	596	603	greater	great	JJR	B-NP
O	604	608	than	than	IN	I-NP
O	609	611	15	15	CD	I-NP
O	611	612	%	%	NN	I-NP
O	613	615	Ki	Ki	NN	I-NP
O	615	616	-	-	HYPH	B-NP
O	616	618	67	67	CD	I-NP
O	619	627	positive	positive	JJ	B-ADJP
O	628	630	by	by	IN	B-PP
O	631	647	immunoperoxidase	immunoperoxidase	NN	B-NP
O	648	656	staining	staining	NN	I-NP
O	656	657	)	)	)	O
O	658	661	and	and	CC	O
O	662	665	low	low	JJ	B-NP
O	666	668	ER	ER	NN	I-NP
O	669	675	levels	level	NNS	I-NP
O	676	677	(	(	(	O
O	677	681	less	less	JJR	B-NP
O	682	686	than	than	IN	I-NP
O	687	689	60	60	CD	I-NP
O	690	695	fmols	fmol	NNS	I-NP
O	695	696	/	/	SYM	B-NP
O	696	698	mg	mg	NN	I-NP
O	699	706	protein	protein	NN	I-NP
O	707	709	by	by	IN	B-PP
O	710	711	a	a	DT	B-NP
O	712	722	monoclonal	monoclonal	JJ	I-NP
O	723	729	enzyme	enzyme	NN	I-NP
O	730	741	immunoassay	immunoassay	NN	I-NP
O	741	742	)	)	)	O
O	742	743	.	.	.	O

O	744	749	Sixty	Sixty	CD	B-NP
O	749	750	-	-	HYPH	I-NP
O	750	755	eight	eight	CD	I-NP
O	756	763	percent	percent	NN	I-NP
O	764	766	of	of	IN	B-PP
B-Cancer	767	773	tumors	tumor	NNS	B-NP
O	774	776	in	in	IN	B-PP
O	777	781	this	this	DT	B-NP
O	782	787	group	group	NN	I-NP
O	788	792	were	be	VBD	B-VP
O	793	801	vimentin	vimentin	NN	B-NP
O	802	810	positive	positive	JJ	B-ADJP
O	811	814	and	and	CC	O
O	815	817	88	88	CD	B-NP
O	817	818	%	%	NN	I-NP
O	819	821	of	of	IN	B-PP
O	822	825	all	all	DT	B-NP
O	826	834	vimentin	vimentin	NN	I-NP
O	834	835	-	-	HYPH	B-NP
O	835	843	positive	positive	JJ	I-NP
B-Cancer	844	850	tumors	tumor	NNS	I-NP
O	851	855	fell	fall	VBD	B-VP
O	856	860	into	into	IN	B-PP
O	861	865	this	this	DT	B-NP
O	866	874	category	category	NN	I-NP
O	874	875	.	.	.	O

O	876	880	More	More	JJR	B-NP
O	881	885	than	than	IN	I-NP
O	886	888	50	50	CD	I-NP
O	888	889	%	%	NN	I-NP
O	890	892	of	of	IN	B-PP
O	893	896	the	the	DT	B-NP
B-Cell	897	902	tumor	tumor	NN	I-NP
I-Cell	903	908	cells	cell	NNS	I-NP
O	909	920	coexpressed	coexpresse	VBD	B-VP
O	921	929	vimentin	vimentin	NN	B-NP
O	930	933	and	and	CC	I-NP
O	934	941	keratin	keratin	NN	I-NP
O	941	942	.	.	.	O

O	943	947	Thus	Thus	RB	B-ADVP
O	947	948	,	,	,	O
O	949	957	vimentin	vimentin	NN	B-NP
O	958	968	expression	expression	NN	I-NP
O	969	972	may	may	MD	B-VP
O	973	975	be	be	VB	I-VP
O	976	983	helpful	helpful	JJ	B-ADJP
O	984	986	in	in	IN	B-PP
O	987	998	identifying	identify	VBG	B-VP
O	999	1000	a	a	DT	B-NP
O	1001	1012	substantial	substantial	JJ	I-NP
O	1013	1019	subset	subset	NN	I-NP
O	1020	1022	of	of	IN	B-PP
O	1023	1025	ER	ER	NN	B-NP
O	1025	1026	-	-	HYPH	B-NP
O	1026	1037	independent	independent	JJ	I-NP
B-Cancer	1038	1044	breast	breast	NN	I-NP
I-Cancer	1045	1055	carcinomas	carcinoma	NNS	I-NP
O	1056	1060	with	with	IN	B-PP
O	1061	1065	poor	poor	JJ	B-NP
O	1066	1076	prognostic	prognostic	JJ	I-NP
O	1077	1087	indicators	indicator	NNS	I-NP
O	1087	1088	.	.	.	O

